NICE U-turn sees Akcea's Waylivra win NHS funding

Pharma Times

18 September 2020 - Akcea Therapeutics UK's Waylivra (volanesorsen), the first and only therapy for Familial Chylomicronaemia Syndrome (FCS), will be funded on the NHS after all, following a u-turn by the National Institute for Health and Care Excellence (NICE).

FCS is the name for a group of rare genetic disorders that affect between 55 and 110 people in England. 

The condition results in very high levels of triglycerides in the blood, causing symptoms such as repetitive episodes of severe abdominal pain, unpredictable and recurrent episodes of acute pancreatitis, enlargement of the liver and spleen and fatigue.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder